ABOUT CYTIVA
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
PRODUCT VIDEOS
FEATURED PRODUCTS
-
Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.
-
Research Use Only (RUO) lipid nanoparticle (LNP) reagents to deliver RNA into hematopoietic stem cells (HSCs) for cell and gene therapy applications.
-
Off-the-shelf, research use only lipid nanoparticle (LNP) reagents to deliver RNA into T-cells.
-
Bring confidence to filtration with an automated single‑use filtration system for pilot‑ and small‑scale manufacturing. This system is intended for crossflow filtration applications in both upstream and downstream workflows.
-
Explore a variety of cell lines, high-performance cell culture media, and single-use bioreactors to suit your process needs for any cell type.
-
Explore scalable and flexible single-use solutions from design to delivery that can help you overcome challenges throughout adeno-associated virus (AAV) manufacturing workflow.
-
Learn about a scalable, single-use platform with built-in automation and regulatory compliance that enables standardized manufacturing workflows for mRNA-LNP drug product production.
-
The NanoAssemblr® commercial formulation system is an automated, single-use system for the clinical and commercial production of lipid nanoparticles (LNPs) under cGMP conditions. Designed for efficient changeover and robust manufacturing processes, the system enables operational flexibility and standardized manufacturing of genomic medicines.
-
Discover a one-stop-shop for LNP technologies that provides access to expertise in formulation and analytics for successful outcomes for payload and target applications. Explore end-to-end biopharma services and systems.
-
Designed for small-scale manufacturing, this single-use liquid chromatography system offers the performance and documentation required for a GMP-regulated environment.
-
Learn about coated magnetic particles that easily isolate and extract mRNA from a variety of sources and enable you to perform RT-PCR cDNA library construction, affinity purification, and more.
-
Synthesize oligonucleotides at scales of 10–100 mmol for early to mid-phase clinical trials or for diagnostic kits.
-
Looking for a user-friendly and compact oligonucleotide synthesizer with a large scale range? Discover a pilot-scale system that will take your drug through clinical development.
-
Explore systems for automated oligonucleotide synthesis, offered at a range of scales to support easy process development, optimization, scale up and transfer. Find the system that matches your needs.
-
The rise in approved oligo therapeutics has led to increased pressure on oligo manufacturers. Learn about modern chromatography resins, how they can help increase productivity in manufacturing, and more.
-
Discover the platform for oligonucleotide development and scale-up that is the result of 30 years of collaboration with leading oligonucleotide pharma. Explore this solution's benefits, specifications, and more.
-
OligoProcess covers a range of 10 to 1800 mmol and is suitable for quantities required in clinical phases and commercial production.
-
By combining disruptive technology platforms with unparalleled genomic medicine development expertise, we're positioned to accelerate the development of LNP formulations and drug products.
-
Explore how consistent mixing, low-volume workflows, and scale-ready design help maintain LNP quality from discovery through clinical development—reducing risk and preserving data continuity.
-
GenVoy-ILM™ T Cell Kit for mRNA, Ignite is an lipid nanoparticle (LNP) reagent mix optimized for the delivery of messenger RNA (mRNA) or Cas9 mRNA/sgRNA into activated human primary T cells.
BROCHURES
- A Comprehensive Upstream Platform For Gene Therapy Applications
- AAV Manufacturing Workflow
- Single-Use System For Clinical And Commercial Production Of LNPs
- Services For Advancing mRNA-LNPs From Bench To Clinic
- Advance, Scale And Simplify LNP Formulation
- GenVoy-ILM™ T Cell Kit For mRNA, Ignite™
- A Next-Generation Technology For The Power To Scale
- T Cell Kit For mRNA On NanoAssemblr Spark
- NanoAssemblr® GMP System: Power To Commercialize
- GenVoy-ILM™: Power To Explore
- NanoAssemblr® Spark™: Freedom To Discover
WEBINARS AND PODCASTS
APPLICATION NOTES
- Discover A System That Can Be Used With Various Cell Culture Media
- Developing CAR T Therapies With A Cell Therapy Manufacturing Platform
- Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors
- Scale-Up Of AAV Production In Fixed-Bed Bioreactors
- mRNA Manufacturing With Fed-Batch In Vitro Transcription
- Oligonucleotide Purification And Synthesis
- Cell Culture Media Mixing In A Benchtop Single-Use Mixer
- Assessing Particle Generation In A Single-Use Mixing System
- A Transient Cell Line To Produce rAAV With Low-Level hcDNA Encapsidation
- How To Successfully Isolate Your T Cells
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.
-
Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.
-
In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.
-
Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.
-
Early process decisions shape scalability, consistency, and compliance in autologous CAR T manufacturing. Learn where variability emerges across the workflow and how to plan ahead.
-
Cell therapies are advancing rapidly, but manufacturing delays still limit patient access. Improving operational understanding, reducing risk, and strengthening collaboration may be just as critical.
-
Automation is reshaping CAR T manufacturing. A modular, closed approach with digital integration supports efficient workflows while maintaining critical functional performance under GMP conditions.
-
Scaling CAR T manufacturing demands high expansion without exhaustion. Examine integrated, semi-automated approaches with digital traceability that can improve consistency and preserve cell function.
-
Serum-free media is reshaping CAR T manufacturing. Gain insight into how media-agnostic platforms offer the flexibility to adapt workflows without re-optimization, helping teams streamline processes.
-
New approaches to suspension cell culture and process scaling enable consistent, high-titer rAAV production. Gain insight into a clearer path to scalable manufacturing for gene therapy pipelines.